STRM.BIO is leveraging extracellular vesicles to usher in a new age of Gene Therapies.
Location: United States
Total raised: $8M
Investors 3
| Date | Name | Website |
| - | KdT Ventur... | kdtvc.com |
| 01.10.2021 | Ascension ... | ascensionv... |
| 24.08.2022 | Breakout V... | breakout.v... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.01.2026 | - | $8M | Delos Capi... |
Mentions in press and media 4
| Date | Title | Description |
| 11.01.2026 | STRM.BIO Secures $8M Seed 2, Propelling Non-Viral Gene Therapy Revolution | STRM.BIO, a Cambridge biotech, closed an $8M Series Seed 2 round. It drives non-viral gene therapy innovation. Its MV platform delivers genetic medicines for in vivo cell engineering. Total recent funding hit $16.4M. Funds advance the pipel... |
| 08.01.2026 | STRM.BIO: $8 Million Series Seed 2 Closed To Advance Non-Viral Gene Delivery For In Vivo Cell Engineering And Gene Therapy | STRM.BIO raised $8 million in a Series Seed 2 financing to advance its non-viral gene delivery platform for in vivo cell engineering and gene therapy. The round included funding from Recordati, with continued participation from Boehringer I... |
| 07.01.2026 | STRM.BIO Raises $8M in Series Seed 2 Financing | STRM.BIO, a Cambridge, MA-based biotechnology company advancing non-viral delivery technologies for in vivo cell and gene therapy, raised $8M in Series Seed 2 financing. The round was led by Recordati with participation form Boehringer Inge... |
| - | STRM.BIO | “Bringing Gene Therapy to Life” |